Activated PI3 kinase delta syndrome – Life with Disease

Go back

Activated PI3 kinase delta syndrome (APDS) is a rare genetic disorder that weakens the immune system, making affected individuals vulnerable to repeated infections, unusual immune system problems, and an increased risk of certain cancers. First identified in 2013, this condition can affect both children and adults in vastly different ways, even within the same family.

Prognosis

Understanding what to expect when living with Activated PI3 kinase delta syndrome can feel overwhelming, especially when the disease affects each person so differently. The outlook for someone with APDS depends on many factors, including when the condition is diagnosed, which symptoms develop, and how well those symptoms respond to treatment. This uncertainty makes it especially important to approach prognosis conversations with compassion and honesty.[1]

The severity of APDS varies widely from person to person. Some individuals may experience multiple severe infections and serious complications throughout their lives, while others show only mild symptoms or even remain symptom-free for extended periods.[2] This variability exists even among family members who share the same genetic change, making it difficult for doctors to predict exactly how the disease will progress in any single individual.[6]

One of the more concerning aspects of APDS prognosis relates to the increased risk of developing blood cancers, particularly types called Hodgkin lymphoma (a cancer affecting the lymphatic system) and non-Hodgkin lymphoma (a group of cancers that start in white blood cells). While nodular lymphoid hyperplasia—the buildup of white blood cells that form solid masses—is not cancerous itself, the overactive immune signaling in APDS does create an environment where cancer can develop more easily.[2]

Progressive organ damage represents another serious concern for long-term prognosis. Recurrent respiratory tract infections, if left untreated or inadequately managed, can lead to permanent damage of the airways called bronchiectasis. This condition occurs when the passages leading from the windpipe to the lungs become damaged and widened, causing breathing problems that worsen over time.[2] The longer infections continue without proper treatment, the more likely permanent lung damage becomes.

⚠️ Important
The clinical course of APDS is difficult to predict, which complicates decisions about appropriate therapies. Because the disease can range from asymptomatic in some adults to causing profound immunodeficiency leading to early death in others, regular monitoring and early intervention are crucial for improving outcomes.[6]

Fortunately, the medical understanding of APDS has improved dramatically since its discovery. With earlier diagnosis, targeted therapies, and comprehensive supportive care, many people with APDS can now expect better outcomes than would have been possible even a decade ago. Access to treatments like leniolisib, which directly targets the overactive signaling pathway causing the disease, offers hope for improved quality of life and potentially better long-term survival.[3]

Natural Progression

When APDS goes undiagnosed or untreated, the disease typically follows a pattern that begins in early childhood, though this timeline varies considerably. Most commonly, symptoms emerge when children are younger than one year old, with frequent and severe infections of the ears, sinuses, and respiratory system serving as the earliest warning signs.[10] These are not ordinary childhood infections—they tend to be more persistent, more severe, and require more aggressive treatment than what healthy children experience.

As time passes without proper intervention, these recurring infections take their toll on the body. The respiratory system bears much of this burden. What begins as repeated bouts of bronchitis or pneumonia gradually damages the delicate tissues of the lungs and airways. This chronic inflammation and repeated injury eventually leads to bronchiectasis, where the airways become permanently widened and scarred, unable to clear mucus effectively. This creates a vicious cycle where the damaged airways become even more susceptible to new infections.[2]

Beyond the respiratory system, the immune dysregulation at the heart of APDS causes white blood cells to behave abnormally. These cells, which should be defending the body against threats, instead begin to accumulate in various organs and tissues. Lymph nodes throughout the body swell and remain enlarged—a condition called lymphadenopathy. The spleen, an organ that filters blood and helps fight infections, becomes enlarged as well, a condition known as splenomegaly. These organs can grow so large they become uncomfortable or even cause complications.[3]

White blood cells may also cluster together to form nodular lymphoid hyperplasia, particularly in the moist linings of the airways and digestive tract. While these growths are not cancerous, they can cause problems depending on their location and size. In the intestines, they may contribute to digestive symptoms or complications.[2]

Viral infections present another dimension of the natural progression. People with APDS often develop chronic, active infections with viruses that most healthy individuals can control. Epstein-Barr virus, herpes simplex virus, and cytomegalovirus may establish persistent infections that the weakened immune system cannot adequately suppress.[2] These ongoing viral infections can cause their own symptoms and complications, further compromising overall health.

The immune system’s confusion doesn’t stop at failing to fight infections—it may also turn against the body itself. Many people with untreated APDS develop autoimmunity, where the immune system mistakenly attacks the body’s own tissues and organs. This can manifest as destruction of blood cells, leading to various types of cytopenias (low blood cell counts), inflammatory arthritis affecting the joints, kidney problems like glomerulonephritis, or liver conditions such as sclerosing cholangitis.[5]

Perhaps most concerning in the natural progression of untreated APDS is the gradual increase in cancer risk. The constant overstimulation of white blood cells, combined with their abnormal proliferation, creates conditions favorable for the development of lymphomas. Without intervention to control this abnormal immune activity, the risk of developing these blood cancers increases over time.[3]

Children with APDS may also experience delays in physical growth and development. Short stature and growth delays are reported, particularly in those with APDS type 2. Some children also show neurodevelopmental delays, though the mechanisms behind these effects are not fully understood.[3]

Possible Complications

Beyond the expected course of APDS, numerous complications can arise that represent unexpected or particularly serious developments. Understanding these potential complications helps patients and families recognize when medical attention is urgently needed.

Bronchiectasis stands among the most common and problematic complications. This permanent damage to the airways doesn’t simply remain stable—it can progressively worsen, especially if infections continue. As the airways lose their normal structure and function, breathing becomes increasingly difficult. People with advanced bronchiectasis may experience chronic cough, excessive mucus production, and shortness of breath that limits their physical activities. The damaged airways also become breeding grounds for unusual or drug-resistant bacteria, making subsequent infections harder to treat.[2]

Digestive system complications can significantly impact quality of life. Some individuals with APDS develop gastrointestinal problems that resemble Crohn-like colitis, causing chronic inflammation of the intestines. This can lead to abdominal pain, diarrhea, and difficulty absorbing nutrients. A particularly dangerous complication called intussusception can occur, where one segment of intestine slides into another segment, like a telescope collapsing. This creates a blockage that requires emergency medical attention.[3]

Autoimmune complications can affect virtually any organ system. When the immune system attacks blood cells, it can cause life-threatening conditions. Autoimmune cytopenias include destruction of red blood cells (causing anemia and fatigue), white blood cells (further compromising infection-fighting ability), or platelets (leading to bleeding problems). Autoimmune attacks on joints can cause painful, swollen joints similar to rheumatoid arthritis. Kidney involvement through glomerulonephritis can impair kidney function, while liver inflammation from sclerosing cholangitis affects the bile ducts and liver function.[5]

The development of lymphoma represents one of the most serious complications. While not everyone with APDS will develop cancer, the risk is significantly elevated compared to the general population. Both Hodgkin and non-Hodgkin lymphomas can occur. These cancers of the lymphatic system require aggressive treatment with chemotherapy or radiation, adding another layer of complexity to managing APDS.[2]

Severe, treatment-refractory infections pose immediate dangers. Some individuals develop infections that don’t respond adequately to standard antibiotic or antiviral treatments. These stubborn infections may require hospitalization, intravenous medications, or combinations of multiple drugs. In extreme cases, overwhelming infections can lead to sepsis, a life-threatening condition where the body’s response to infection causes widespread inflammation and organ damage.[3]

Progressive organ damage can accumulate over years. Beyond the lungs, repeated infections and chronic inflammation can affect the liver, leading to hepatomegaly (enlarged liver) or impaired liver function. The spleen, when significantly enlarged, may rupture due to trauma, causing dangerous internal bleeding. Chronic inflammation throughout the body can also contribute to earlier development of cardiovascular problems.[3]

⚠️ Important
Treatment complications can also occur. Immunoglobulin replacement therapy, while generally safe, can occasionally cause allergic reactions, headaches, or rarely, blood clots. More aggressive treatments like hematopoietic stem cell transplantation carry significant risks including graft rejection, graft-versus-host disease, and severe infections during the recovery period when the immune system is rebuilding.[6]

Dental problems appear more prominently in APDS type 2. Some patients experience characteristic dental findings including early tooth loss, unusual tooth structure, or increased susceptibility to dental infections. These oral health issues require regular dental monitoring and preventive care.[3]

Impact on Daily Life

Living with APDS affects nearly every aspect of daily existence, from the most routine activities to major life decisions. The physical burden of the disease combines with emotional and social challenges to create a complex web of adjustments and adaptations.

Physical limitations often dictate what activities are possible or advisable. Frequent infections mean that periods of feeling relatively well alternate with episodes of illness requiring rest and recovery. During infections, fatigue can be overwhelming, making even simple tasks like climbing stairs or preparing meals exhausting. Chronic cough from bronchiectasis may interrupt sleep, leading to persistent tiredness that affects daytime functioning. Enlarged lymph nodes or an enlarged spleen can cause physical discomfort or visible swelling that affects clothing choices and body image.[14]

The need for regular medical treatments shapes daily schedules. People receiving immunoglobulin replacement therapy must arrange for intravenous or subcutaneous infusions, typically every three to four weeks. These treatments take several hours and may cause side effects like headaches or fatigue afterward. Those taking prophylactic antibiotics or antivirals must remember daily medications. Frequent doctor appointments for monitoring and managing symptoms require time away from work, school, or other activities.[3]

Work life requires significant accommodations. The unpredictability of infections makes it difficult to maintain perfect attendance, which can strain relationships with employers or colleagues who may not understand the invisible nature of immune deficiency. People with APDS may need to avoid certain work environments where exposure to infections is high. Those with advanced lung disease may find that jobs requiring physical exertion become impossible. Career choices may be limited by health considerations rather than interests or abilities.[14]

For children and young people, school attendance and academic performance suffer from frequent absences. Missing class due to illness or medical appointments creates gaps in learning that require extra effort to overcome. Physical education classes may need modification if breathing problems or fatigue limit exercise capacity. Social aspects of school—making friends, participating in activities, attending events—become harder when illness keeps you home. Some children require individualized education plans to address their specific needs.[14]

The social impact extends far beyond school or work. Friendships require understanding from others about the need to cancel plans when feeling ill. Social anxiety may develop around eating in public if gastrointestinal symptoms are problematic. Dating and intimate relationships involve explaining a complex medical condition and addressing concerns about genetic inheritance if considering having children. The visible signs of illness—frequent infections, chronic cough, or physical changes from medications—may make people feel self-conscious in social situations.

Hobbies and recreational activities often require modification. Contact sports may be discouraged if the spleen is enlarged due to rupture risk. Swimming in public pools or exercising in crowded gyms may increase infection exposure. Travel becomes complicated by the need to carry medications, access medical care in unfamiliar locations, and avoid high-risk infection environments. Even simple pleasures like attending concerts or movies may feel risky during respiratory virus season.

The emotional toll can be profound. Living with uncertainty about when the next infection will strike, whether a complication will develop, or how the disease will progress creates ongoing anxiety. Depression is common among people with chronic illness, compounded by the limitations APDS places on life activities. Frustration arises when symptoms are dismissed by others who don’t understand the invisible nature of immune deficiency. Some people describe feeling isolated, as if they’re living a different reality from their healthy peers.[14]

Financial stress adds another burden. Medical expenses accumulate from frequent doctor visits, medications, immunoglobulin therapy, and hospitalizations. Even with insurance, copayments and deductibles can be substantial. Lost income from missed work compounds these costs. Some people must reduce work hours or stop working entirely, creating financial hardship. Families may struggle with the costs of genetic testing for relatives or special accommodations for affected children.[1]

Coping strategies become essential. Many people find that maintaining a detailed symptom diary helps them recognize patterns and communicate effectively with healthcare providers. Building a strong relationship with a trusted medical team provides a sense of security. Connecting with others who have APDS, whether through in-person support groups or online communities, reduces feelings of isolation and provides practical advice from those who truly understand. Some find that focusing on what they can control—medication adherence, healthy lifestyle choices, stress management—helps maintain a sense of agency.[14]

Despite these challenges, many people with APDS develop remarkable resilience. They learn to adapt activities rather than abandon them entirely, find creative solutions to limitations, and discover strength they didn’t know they possessed. With proper treatment and support, living a full and meaningful life with APDS is absolutely possible.

Support for Family

Family members play a crucial role in supporting someone with APDS, particularly when it comes to exploring treatment options through clinical trials. Understanding what clinical trials offer and how to navigate them effectively can make a significant difference in accessing cutting-edge care.

Clinical trials represent research studies that test new treatments or ways of using existing treatments. For rare diseases like APDS, clinical trials are particularly important because they offer access to therapies that might not otherwise be available. These studies help researchers understand whether new treatments are safe and effective, gradually building the evidence base that eventually leads to approved medications.[1]

Families should understand that participating in a clinical trial is entirely voluntary. No one can be forced or pressured to enroll, and participants can withdraw at any time without affecting their regular medical care. The decision to participate should be made carefully, weighing potential benefits against risks and considering how the trial requirements fit with the person’s life circumstances.

Finding appropriate clinical trials starts with open communication with the healthcare team. Doctors treating APDS often know about relevant studies and can discuss whether their patient might be eligible. Several online databases also list clinical trials, allowing families to search specifically for APDS studies. The Immune Deficiency Foundation maintains information about clinical trials for primary immunodeficiencies, including APDS, and can be a valuable resource.[1]

When considering a specific trial, families should gather comprehensive information. Understanding the trial’s purpose, what treatment or intervention is being studied, and what the study procedures involve helps set realistic expectations. Questions to ask include: What phase is the trial (early testing for safety or later testing for effectiveness)? How long does participation last? What tests or procedures are required? Are there any costs to participants? Will travel expenses be covered? What happens after the trial ends?

Eligibility criteria determine who can participate. These criteria exist for good scientific reasons—they ensure the study enrolls people whose characteristics make them appropriate for testing the particular intervention. Someone with APDS might not qualify for a specific trial due to age restrictions, previous treatments received, current medications, presence or absence of certain complications, or other health factors. Understanding and accepting these restrictions prevents disappointment and helps focus the search on appropriate opportunities.

The informed consent process is critical. Before enrolling, potential participants receive detailed information about the study in writing and through conversations with research staff. This consent document explains everything about the study, including potential risks and benefits. Families should read this document carefully, discuss it thoroughly, and ask questions about anything unclear. The research team should never pressure anyone to make an immediate decision—taking time to consider all aspects is expected and appropriate.

Practical support from family members makes trial participation more feasible. Many studies require multiple visits to the research center, sometimes in distant locations. Family members can help arrange transportation, accompany the patient to appointments, take notes during discussions with research staff, and provide emotional support throughout the process. For studies involving children, parents must make informed decisions on behalf of their child while considering the child’s own preferences and understanding as appropriate for their age.

Because APDS is genetic and inherited in an autosomal dominant pattern (meaning only one copy of the changed gene from one parent can cause the condition), family members of a diagnosed individual should consider genetic testing themselves. Even relatives without symptoms might carry the genetic variant and could pass it to their children. Genetic counseling helps families understand inheritance patterns, assess their own risk, make informed decisions about testing, and understand implications for family planning.[1]

Family support extends beyond clinical trial participation. Relatives can advocate for their loved one by learning about APDS, helping communicate with healthcare providers, ensuring medications and treatments are obtained and used correctly, and recognizing when symptoms require medical attention. Emotional support—listening without judgment, validating feelings, maintaining hope while being realistic, and simply being present—proves invaluable for someone managing a chronic disease.

Siblings of children with APDS need attention too. They may feel neglected when the sick child requires so much parental time and resources, worry about their sibling’s health, or experience guilt if they themselves are healthy. Parents should make time for healthy siblings, explain APDS in age-appropriate terms, and encourage them to express their feelings.

Extended family and friends often want to help but don’t know how. Specific requests work better than general offers. Families might appreciate help with meals, childcare for healthy siblings, transportation to appointments, or assistance with household tasks during illness episodes. Creating a support network distributes the burden and prevents caregiver burnout.

Support groups, both in-person and online, connect families affected by APDS. Sharing experiences with others who truly understand the challenges reduces isolation and provides practical advice from those who’ve navigated similar situations. Global APDS communities on social media platforms allow people from different countries to connect, particularly valuable for those living in areas where APDS is extremely rare and meeting others locally may be impossible.[14]

💊 Registered drugs used for this disease

List of officially registered medicines that are used in the treatment of this condition, based only on the provided sources:

  • Leniolisib (Joenja) – A selective PI3K delta inhibitor approved in 2023, recommended as first-line treatment for significant lymphoproliferative disease including lymphadenopathy and splenomegaly. It directly targets the overactive PI3K delta signaling pathway that is the hallmark of APDS. Approved for patients aged 12 and older.[1][3][4]
  • Sirolimus – An inhibitor of the mammalian target of rapamycin (mTOR) recommended for individuals with lymphoproliferative disease or organomegaly when leniolisib is unavailable. Used off-label due to its immunosuppressive and antiproliferative properties.[3][6]

Ongoing Clinical Trials on Activated PI3 kinase delta syndrome

  • Study on Leniolisib for Patients with Activated Phosphoinositide 3-Kinase Delta Syndrome and Impaired Liver Function

    Not recruiting

    1 1
    Investigated diseases:
    Germany Hungary
  • Study on the Effects of Leniolisib in Patients with Activated Phosphoinositide 3-Kinase Delta Syndrome

    Not recruiting

    1 1
    Investigated diseases:
    Germany
  • Study on the Effects of Leniolisib in Children Aged 1 to 6 with Activated PI3K Delta Syndrome (APDS)

    Not recruiting

    1 1 1
    Investigated diseases:
    Portugal Spain
  • Study of Leniolisib for Children Aged 4 to 11 with Activated PI3K Delta Syndrome

    Not recruiting

    1 1 1
    Investigated diseases:
    France

References

https://primaryimmune.org/understanding-primary-immunodeficiency/types-of-pi/activated-pi3k-delta-syndrome-apds

https://medlineplus.gov/genetics/condition/activated-pi3k-delta-syndrome/

https://www.ncbi.nlm.nih.gov/books/NBK611655/

https://en.wikipedia.org/wiki/Activated_PI3K_delta_syndrome

https://www.orpha.net/en/disease/detail/397596

https://pmc.ncbi.nlm.nih.gov/articles/PMC6137162/

https://www.ncbi.nlm.nih.gov/books/NBK611655/

https://medlineplus.gov/genetics/condition/activated-pi3k-delta-syndrome/

https://www.babraham.ac.uk/news/2025/06/first-patient-treatment-received-APDS

https://www.healio.com/news/allergy-asthma/20250509/first-step-in-managing-activated-pi3k-delta-syndrome-is-recognizing-it

https://primaryimmune.org/understanding-primary-immunodeficiency/types-of-pi/activated-pi3k-delta-syndrome-apds

https://www.ncbi.nlm.nih.gov/books/NBK611655/

https://pmc.ncbi.nlm.nih.gov/articles/PMC10432830/

https://rarerevolutionmagazine.com/digitalspotlight/life-with-activated-pi3k-delta-syndrome/

https://www.immunodeficiencyuk.org/activated-pi3k-delta-syndrome-apds-2/

FAQ

Is APDS contagious or can I catch it from someone who has it?

No, APDS is not contagious. It is a genetic condition caused by changes in specific genes that you are born with. You cannot catch it from being around someone who has APDS. However, because people with APDS are more susceptible to infections, they may get sick from germs more easily than healthy individuals.[2]

If my child has APDS, will my other children automatically have it too?

Not necessarily. APDS is inherited in an autosomal dominant pattern, meaning only one changed gene is needed to cause the condition. If a parent has APDS, each of their children has a 50% chance of inheriting the genetic variant. However, some APDS cases result from new (de novo) genetic changes that occur for the first time in the affected person, meaning neither parent carries the variant. Genetic testing and counseling can clarify the situation for individual families.[1][14]

Why wasn’t APDS diagnosed earlier if it’s genetic from birth?

APDS was only identified as a distinct condition in 2013, so it couldn’t be diagnosed before then. Prior to its discovery, patients were often given other diagnoses like Common Variable Immunodeficiency (CVID) or general primary immunodeficiency. Even now, because APDS is rare and symptoms vary widely between individuals, diagnosis can take years after symptoms first appear. Some people don’t develop obvious symptoms until later in childhood or even adulthood, further delaying recognition.[1][14]

Can APDS be cured completely?

There is currently no cure that eliminates APDS entirely. However, hematopoietic stem cell transplantation (bone marrow transplant) can potentially replace the faulty immune system with a healthy one and is reserved for severe cases with progressive organ damage or life-threatening complications. New targeted therapies like leniolisib address the root cause of APDS by blocking the overactive signaling pathway, significantly improving symptoms and quality of life, though patients need ongoing treatment. Most people manage APDS with a combination of treatments rather than achieving a complete cure.[3][6]

What’s the difference between APDS type 1 and type 2?

APDS type 1 is caused by changes in the PIK3CD gene, while APDS type 2 results from changes in the PIK3R1 gene. Both affect the same PI3K delta enzyme but through different protein subunits. Clinically, they are very similar, though APDS type 2 tends to show more prominent short stature, higher frequency of gastrointestinal infections, and characteristic dental problems. The treatment approach is generally the same for both types.[3][10]

🎯 Key takeaways

  • APDS is one of the youngest recognized diseases, discovered only in 2013, yet it may have affected families for generations under different diagnostic labels.
  • The same genetic variant can cause wildly different experiences—severe illness in one family member and minimal symptoms in another—making prediction nearly impossible.
  • Leniolisib represents a breakthrough as the first drug specifically approved for APDS, directly targeting the overactive enzyme causing the disease rather than just managing symptoms.
  • Genetic testing is the only definitive way to diagnose APDS, and family members should consider testing even without symptoms since they might carry and pass on the variant.
  • Recurrent ear, sinus, and lung infections starting in infancy are the typical first warning signs, though diagnosis often takes years after symptoms begin.
  • The increased risk of lymphoma makes regular monitoring essential, as catching cancer early dramatically improves treatment success.
  • Online communities have transformed life for people with APDS, connecting individuals across continents who might otherwise never meet anyone else with their rare condition.
  • The complexity of APDS means management requires a team approach—immunologists, pulmonologists, gastroenterologists, and other specialists working together for comprehensive care.